Clinical trial
A Phase 1/2a, Open-Label, Dose Finding and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sonrotoclax (BGB-11417) in Combination With Other Agents in Pediatric Patients Aged 6 Months to 17 Years, With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
NCT07770698 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a, Open-Label, Dose Finding and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sonrotoclax (BGB-11417) in Combination With Other Agents in Pediatric Patients Aged 6 Months to 17 Years, With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
- Lead sponsor
- BeOne Medicines
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- September 30, 2031
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, acute myeloid leukemia, b-cell acute lymphoblastic leukemia, pediatric all, pediatric all, b cell, pediatric all, relapsed, pediatric aml, pediatric cancer, r/r aml, r/r b-cell all, refractory acute myeloid leukemia, relapsed acute myeloid leukemia